Pathophysiologic Rationale for Dual Therapy in Diabetic Retinal Disease

Diabetic retinopathy (DR) and diabetic macular edema (DME) arise from a chronic hyperglycemic milieu that activates multiple interconnected pathogenic cascades. Vascular endothelial growth factor (VEGF) is a primary driver of vascular leakage and neovascularization, but it does not act alone. Angiopoietin-2 (Ang-2) destabilizes pericytes, making retinal capillaries more prone to leakage and inflammation. Pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) further compromise the blood-retinal barrier. Mechanical traction from vitreoretinal adhesion also contributes to edema in some eyes. Monotherapy with a single anti-VEGF agent often fails to address these parallel pathways, leaving residual fluid and requiring frequent retreatments.

Dual therapy attacks the disease from multiple angles. The rationale includes: (1) neutralizing VEGF-driven angiogenesis while also stabilizing vessels via Ang-2 blockade or corticosteroid-mediated tightening of endothelial junctions; (2) reducing the injection burden by extending the duration of action; (3) rescuing eyes with suboptimal response to anti-VEGF alone; and (4) targeting both vascular and inflammatory components to achieve more robust anatomical and functional outcomes. The most well-studied combinations pair anti-VEGF agents (ranibizumab, aflibercept, or bevacizumab) with either laser photocoagulation or sustained-release corticosteroids. A newer paradigm uses bispecific molecules that simultaneously bind VEGF and Ang-2 in a single injection.

Clinical Trial Evidence for Dual Therapy

Anti-VEGF Plus Macular Laser Photocoagulation

Laser photocoagulation was the cornerstone of DME management before anti-VEGF agents revolutionized care. The DRCR.net Protocol I (2010) randomized DME eyes to four arms: laser alone, ranibizumab with prompt laser, ranibizumab with deferred laser (≥24 weeks), or triamcinolone with prompt laser. At one year, the ranibizumab plus deferred laser group gained a mean of 9 letters on the ETDRS chart—significantly superior to laser alone (3 letters). The combination group also required fewer injections over subsequent years. Protocol I demonstrated that anti-VEGF should be primary, but adjunctive laser can reduce retreatment frequency and sustain long-term gains in some eyes.

However, later trials tempered enthusiasm. The DRCR.net Protocol S (2015) compared ranibizumab monotherapy to panretinal photocoagulation (PRP) for proliferative DR, finding non-inferiority for ranibizumab with fewer side effects, but did not specifically test combination therapy. A Cochrane systematic review concluded that adding laser to anti-VEGF does not consistently improve visual acuity versus anti-VEGF alone, though it may reduce the need for subsequent injections. The VISTA and VIVID trials (2014) compared intravitreal aflibercept alone or with minimally invasive laser. Combination arms showed greater reduction in central retinal thickness (CRT) at 52 weeks but no significant visual benefit over aflibercept monotherapy.

In clinical practice, laser augmentation is reserved for eyes with persistent subretinal fluid, hard exudates, or when injection frequency must be minimized due to cost or patient adherence issues. The DRCR.net Protocol T (2015) further reinforced that anti-VEGF monotherapy yields superior visual outcomes to laser combination in most cases, though subgroup analyses suggested that eyes with poorer baseline vision may benefit from the addition of laser. A newer approach using subthreshold micropulse laser, which causes less damage to the retina, is under investigation in the LIGHT-AND-FLARE trial (NCT03792347) as a safer adjunct to anti-VEGF therapy.

Anti-VEGF Combined with Corticosteroids

Corticosteroids address inflammation and vascular leakage by stabilizing tight junctions, suppressing cytokines, and downregulating VEGF expression. The most compelling evidence for this combination comes from the DRCR.net Protocol U (2013). This trial enrolled eyes with center-involving DME that had persistent edema despite at least three prior anti-VEGF injections. Patients were randomized to continue ranibizumab alone or receive ranibizumab plus a dexamethasone intravitreal implant. At 24 weeks, the combination group achieved a greater mean reduction in CRT (−152 vs. −91 μm, P<0.001), but visual acuity gains were not statistically different (+3.5 vs. +2.8 letters). Importantly, the combination arm had higher rates of intraocular pressure (IOP) elevation (23% vs. 8%) and cataract progression in phakic eyes. Protocol U established that adding a steroid can improve anatomical outcomes in refractory DME, but with trade-offs in safety.

The BEVORDEX trial (2016) compared dexamethasone implant alone versus bevacizumab plus dexamethasone in treatment-naïve DME. At 12 months, the combination group showed a greater mean BCVA gain (+9.5 vs. +7.0 letters) and required fewer injections (7 vs. 11). A meta-analysis in Ophthalmology Retina confirmed a significant CRT reduction benefit for combination over anti-VEGF alone at 12 months, but visual gains were similar. More recent studies have explored repeated steroid implants alongside anti-VEGF in a treat-and-extend regimen. A consensus is emerging that pseudophakic eyes with chronic or severe DME often benefit most from periodic steroid augmentation, provided IOP is managed with topical drops or selective laser trabeculoplasty.

Subgroup Analyses: Who Benefits Most?

Post-hoc analyses of Protocol U and other trials indicate that eyes with baseline CRT >400 μm, cystoid macular edema, or a history of prior vitrectomy derive the greatest anatomical benefit from anti-VEGF-steroid combination. The presence of epiretinal membrane or vitreomacular traction may also predict a better response. Conversely, phakic eyes carry a higher risk of corticosteroid-induced cataract, which can negate visual gains. Many clinicians now reserve combination steroid therapy for pseudophakic eyes or use lower-dose implants (e.g., fluocinolone acetonide, which has a lower IOP elevation profile). The FAME studies (2011) showed that the 0.2 μg/day fluocinolone acetonide implant reduces IOP rise compared to the 0.5 μg/day dose, making it a safer option for combination with anti-VEGF. The LOTUS trial (NCT01518335) is currently evaluating repeat dexamethasone implants in combination with ranibizumab for chronic DME, with 3-year data anticipated soon.

Bispecific Antibodies: Built-in Dual Therapy

The most transformative advance in dual therapy is the bispecific antibody faricimab (Vabysmo, Genentech/Roche). Faricimab simultaneously binds VEGF-A and Ang-2 with high affinity, targeting both angiogenic and inflammatory pathways in a single molecule. Ang-2 inhibition complements anti-VEGF by promoting pericyte re-coverage and vascular stability. The phase 3 YOSEMITE and RHINE trials (2022) randomized DME eyes to faricimab 6 mg every 8 weeks (q8w), faricimab 6 mg every 16 weeks (q16w) after a loading phase, or aflibercept 2 mg q8w. Both faricimab arms met the primary endpoint of non-inferiority in BCVA change. Notably, the q16w faricimab regimen—requiring only 3 injections in the first year—achieved comparable vision gains to q8w aflibercept, dramatically reducing treatment burden. Nearly 40% of eyes on q16w faricimab maintained retinal drying at one year. Faricimab received FDA approval for DME in February 2022.

Another bispecific candidate, brolucizumab (Beovu, Novartis), is a single-target anti-VEGF with an ultra-high molar dose. While not truly dual therapy, its superior wet-drying ability may allow combination with steroids in non-responders. Phase 3 data for its use in combo are pending. Ongoing trials are also exploring dual-target small interfering RNA (siRNA) approaches that simultaneously suppress VEGF and Ang-2 gene expression. The ANGPT2-VEGF-A siRNA (SYL1801) is entering phase 2 for DME, with preliminary data showing a safety profile similar to anti-VEGF alone.

Port Delivery Systems and Future Implant Technologies

The Port Delivery System with Ranibizumab (PDS) was evaluated in the Archway trial (2020), which achieved visual outcomes comparable to monthly ranibizumab injections for DME using a refillable implant that releases drug continuously. While PDS is a monotherapy, future iterations may incorporate a second drug. An ongoing phase 2 trial (NCT04567550) is testing a dual-chamber PDS containing ranibizumab and a sustained-release corticosteroid. Other investigational systems include biodegradable implants that co-deliver anti-VEGF and steroid in a single injection, aiming for 6-month durability. The ReSphere trial (NCT04482504) is evaluating a hydrogel-based implant that releases aflibercept and dexamethasone sequentially, with early results showing reduced injection burden and improved CRT reduction in a small cohort.

Safety Profile of Dual Therapy

Dual therapy inherently expands the risk window. In anti-VEGF plus laser trials, no additional systemic safety signals were observed, but local risks include choroidal neovascularization rebound and laser scar enlargement. For anti-VEGF plus corticosteroids, the major concerns are IOP elevation (reported in 15-30% of eyes) and accelerated cataract formation in phakic eyes. The SAFODEX study (2013) of combined ranibizumab-dexamethasone reported that 22% of eyes required IOP-lowering drops; most were managed medically. In Protocol U, IOP elevation occurred within the first six weeks and was generally controllable. Cataract progression was dose-dependent; the lower-dose steroid implants (Iluvien, 0.2 μg/day) had a significantly lower cataract rate compared to higher-dose formulations.

Bispecific agents like faricimab have shown a favorable safety profile to date. In YOSEMITE and RHINE, rates of IOP elevation and cataract were similar to aflibercept. No unexpected ocular or systemic adverse events emerged. Rare cases of intraocular inflammation (0.6%) and retinal vasculitis (<0.1%) were reported, consistent with anti-VEGF class effects. Ongoing post-marketing surveillance will further characterize the long-term risk-benefit balance. The FARISCORE study (NCT05555407) is a prospective registry tracking real-world safety outcomes for faricimab in DME and wet AMD, with interim 1-year data showing no new safety signals.

Emerging Strategies and Future Directions

Ongoing Clinical Trials

The PANORAMA trial (NCT02718326) is evaluating combined ranibizumab and laser in non-proliferative DR to prevent progression to proliferative disease. Early results suggest a 50% reduction in the development of neovascularization. The RECOVERY study (NCT02509598) is testing ranibizumab plus oral fenofibrate for DME, targeting both VEGF and lipid-mediated inflammation. The LADDLE trial (NCT02882651) is investigating the addition of topical NSAIDs to anti-VEGF to reduce residual inflammation. Another innovative approach involves gene therapy: vectors that co-express anti-VEGF antibodies (e.g., aflibercept-like molecule) and anti-inflammatory cytokines (e.g., IL-10 or IL-1 receptor antagonist) are entering early-phase human trials. The RGX-314 gene therapy (NCT04832750) is being tested for DME with a second-generation vector that also expresses a soluble VEGF receptor to improve durability.

Personalized Dual Therapy with Artificial Intelligence

The American Academy of Ophthalmology's 2021 Preferred Practice Pattern now acknowledges that dual therapy may reduce treatment burden in select patients. Artificial intelligence (AI) algorithms analyzing OCT biomarkers—such as the size of cystoid spaces, the integrity of the ellipsoid zone, and the presence of hyperreflective foci—are being developed to predict which eyes will benefit from adding a steroid to anti-VEGF. Similarly, machine learning models that integrate imaging, systemic metabolic data, and genetic polymorphisms may eventually guide the choice between bispecific agents, combinational injections, or port delivery systems. The SMART-DME trial (NCT04238624) is using a AI-powered OCT reading center to randomize eyes to either ranibizumab monotherapy or ranibizumab plus dexamethasone based on the algorithm's prediction, with 1-year results expected in 2025.

Cost-Effectiveness and Access

Bispecific antibodies, while premium-priced, may reduce overall costs by lowering injection frequency and clinic visits. Health technology assessments from the UK NICE and US ICER have found faricimab cost-effective for DME when used at the 16-week interval. Combination with laser or steroids is already widely reimbursed, though generic corticosteroids (e.g., triamcinolone acetonide) offer a lower-cost alternative for steroid-responsive eyes. Ongoing efforts in low-resource settings are exploring the use of compounded bevacizumab with non-proprietary dexamethasone as a cost-effective dual-therapy option. The COST-OPTM trial (NCT05098786) is comparing the cost-utility of faricimab versus aflibercept plus dexamethasone in persistent DME, with interim analyses suggesting similar quality-adjusted life years at lower overall cost for the faricimab arm.

Practical Takeaways for Clinicians

When considering dual therapy, clinicians should weigh the following: (1) For treatment-naïve DME, anti-VEGF monotherapy remains first-line. Dual therapy is best reserved for eyes with suboptimal response—defined as persistent CRT >300 μm or less than 5-letter gain after three monthly anti-VEGF injections. (2) In pseudophakic eyes, adding a steroid implant can improve anatomical outcomes with manageable cataract risk. (3) In phakic eyes with good baseline acuity, faricimab's bispecific approach avoids IOP and cataract concerns while offering extended durability. (4) In eyes with chronic DME and significant macular ischemia (enlarged foveal avascular zone), combination therapy may not improve vision but can still reduce edema and prevent further ischemia. (5) Always monitor IOP and consider prophylactic drops or early laser trabeculoplasty when using corticosteroids. (6) For eyes on faricimab, the 16-week regimen should be attempted only after a loading phase; if fluid persists at month 4, switch to 8-week dosing. (7) Emerging evidence supports the use of baseline OCT-A (optical coherence tomography angiography) to detect areas of capillary non-perfusion, which may predict a better response to Ang-2-targeted therapy.

Conclusion

The clinical trial landscape for dual therapy in diabetic retinal diseases has evolved from early combination of laser and anti-VEGF to sophisticated bispecific antibodies that achieve multi-pathway blockade in a single injection. While the visual gains from adding laser or corticosteroids to anti-VEGF monotherapy have been modest in aggregate, certain patient subgroups derive significant anatomical benefit. The success of faricimab and the investigation of port delivery systems suggest that the future of dual therapy lies in both pharmacologic innovation and device-based sustained release. Clinicians should weigh improved anatomical outcomes and reduced injection frequency against the potential for IOP elevation and cataract. As more data from ongoing trials emerge, personalized dual therapy—guided by biomarkers, imaging, and patient preference—will become an integral part of the modern ophthalmologist's armamentarium for diabetic eye disease.